However, there are now two large outcome trials of SGLT2 inhibitors in patients following an acute MI, Empagliflozin in Patients Post Myocardial Infarction (EMPACT‐MI), and Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack (DAPA‐MI).23, 39. This evidence concerns the gene SLC5A2 and myocardial infarction.